Clinical

Dataset Information

0

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer


ABSTRACT: The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and associated with improved activity in KRAS codon 12-13 wild-type patients. BRAF and other RAS rare mutations have been suggested as additional potential biomarkers for anti-EGFR agents in metastatic colo-rectal cancer. The present study aims to demonstrate the feasibility and the activity of the first-line combination of the GONO-FOLFOXIRI regimen and Panitumumab in molecularly selected metastatic colo-rectal cancer patients.

DISEASE(S): Metastatic Colorectal Carcinoma,Metastatic Colo-rectal Cancer,Colorectal Neoplasms

PROVIDER: 2107060 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2010-11-13 | GSE24713 | GEO
2010-11-13 | E-GEOD-24713 | biostudies-arrayexpress
2010-02-17 | E-GEOD-14538 | biostudies-arrayexpress
2016-06-10 | E-GEOD-83161 | biostudies-arrayexpress
2010-01-23 | GSE14538 | GEO
2016-06-10 | GSE83161 | GEO
2024-04-09 | GSE263513 | GEO
2013-05-14 | E-GEOD-46862 | biostudies-arrayexpress
2013-05-14 | GSE46862 | GEO
| PRJNA472989 | ENA